19.94k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
|Watchlist||Change today||1-month return||1-year return||Total return|
|The Fight Against COVID19||+2.14%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||158.46||-4.30||-2.64%||4:00 pm GMT-5||14.42M||8.18M||416.54B|
|ABBV||AbbVie Inc.||107.74||+0.41||+0.38%||4:02 pm GMT-5||9.25M||7.22M||190.26B|
|PFE||Pfizer Inc.||33.49||-0.33||-0.98%||4:02 pm GMT-5||41.46M||41.92M||186.15B|
|SNY||Sanofi||45.89||+0.09||+0.20%||4:00 pm GMT-5||3.13M||2.75M||115.12B|
|GSK||GlaxoSmithKline plc||33.61||-0.77||-2.24%||4:00 pm GMT-5||7.64M||5.52M||83.91B|
|GILD||Gilead Sciences, Inc.||61.4||-1.39||-2.21%||4:00 pm GMT-5||10.40M||9.01M||76.97B|
|MRNA||Moderna, Inc.||154.81||+6.43||+4.33%||4:00 pm GMT-5||13.45M||21.63M||61.26B|
|TAK||Takeda Pharmaceutical Company Limited||16.71||-0.04||-0.24%||4:00 pm GMT-5||4.78M||3.62M||53.07B|
|REGN||Regeneron Pharmaceuticals, Inc.||450.57||-2.62||-0.58%||4:00 pm GMT-5||1.19M||1.04M||48.27B|
|BNTX||BioNTech SE||109.03||-3.30||-2.94%||4:00 pm GMT-5||1.01M||3.12M||26.25B|
|NVAX||Novavax, Inc.||231.23||+9.73||+4.39%||4:00 pm GMT-5||2.03M||4.69M||15.55B|
|VIR||Vir Biotechnology, Inc.||62.63||-1.48||-2.31%||4:00 pm GMT-5||952.88k||1.60M||7.98B|
|INO||Inovio Pharmaceuticals, Inc.||11.1||-0.39||-3.39%||4:00 pm GMT-5||12.26M||15.69M||2.27B|
British-based drugmaker AstraZeneca plc (NASDAQ: AZN) has sold its 7.7% stake in Moderna Inc. (NASDAQ: MRNA) for more than $1 billion, the Times reported Sunday. What Happened: AstraZeneca disposed of its stake in Moderna following the U.S. biotechnology company’s coronavirus vaccine breakthrough, according to the Times report. It isn't clear over what period AstraZeneca sold its holding, the report added. The news of the stake sale comes just as Johnson & Johnson’s (NYSE: JNJ) single-shot coronavirus vaccine candidate received approval as the third vaccine for emergency use in the U.S. Moderna’s coronavirus vaccine was approved by U.S. regulators in December last year for emergency use against COVID-19. While reporting its fourth-quarter financial results in late February, Moderna said it expects product sales of $18.4 billion from the vaccine this year. Why It Matters: AstraZeneca’s 7.7% stake made it the second-largest investor in Moderna last year. The company could use the cash from the stake sale to develop its own drugs and complete its $39 billion acquisition of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). AstraZeneca, which developed its COVID-19 vaccine in partnership with Oxford University, sells the vaccine on a non-commercial basis, unlike Moderna’s vaccine. The company’s vaccine has not yet received approval in the U.S. As per the Times report, AstraZeneca will continue its partnership with Moderna on other disease treatments and may sell its COVID-19 vaccine on a commercial basis in the future if the virus becomes endemic. Price Movement: AstraZeneca’s shares closed more than 1% lower at $48.38 on Friday, while Moderna’s shares closed 4.3% higher at $154.81. Photo by Marco Verch on Flickr See more from BenzingaClick here for options trades from BenzingaPfizer, Moderna, J&J Pledge To Make 240M COVID-19 Vaccine Doses Available In US By March-EndModerna Prepares To Increase Doses In Each COVID-19 Vaccine Vial To Counter Production Woes© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Initial deliveries of the newly approved Johnson & Johnson COVID-19 vaccine should start on Tuesday, senior Biden administration officials said on Sunday, saying they hoped to boost lagging vaccination rates among minorities. The officials acknowledged that vaccination rates among Black and brown Americans were "not where we ultimately want them to be", but said measures had been put in place to boost those numbers, and sought to assure minorities that the vaccines were safe. Federal officials were also closely monitoring distribution to ensure it was equitable, they said.
The report added that it was not clear over what period British-based AstraZeneca sold its holding in Moderna. AstraZeneca and Moderna did not immediately respond to requests for comment. AstraZeneca is retaining partnership with Moderna on other disease treatments and could sell its AstraZeneca/Oxford University COVID-19 vaccine on a commercial basis in future if the virus becomes endemic, the report added.